Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13996163 | 0.87 | MEN1 (0.31) | KMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5027812 | 0.85 | EPHX1 (0.45) | EPHX1KMT2AMAPTSMN1; SMN2GAA | |
| SCHEMBL5034598 | 0.85 | PKM (0.32) | — | |
| SCHEMBL13996162 | 0.76 | — | — | |
| SCHEMBL13527455 | 0.74 | MEN1 (0.30) | KMT2AMAPTMEN1 | |
| SCHEMBL14419213 | 0.73 | KMT2A (0.31) | KMT2AALDH1A1HTT | |
| SCHEMBL5030340 | 0.72 | SMN1; SMN2 (0.33) | KMT2AMAPTSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL13996165 | 0.72 | KMT2A (0.33) | KMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5030401 | 0.70 | EPHX1 (0.38) | EPHX1KMT2AMAPTSMN1; SMN2GAA | |
| SCHEMBL4793343 | 0.69 | MAPT (0.37) | KMT2AMAPTSMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20050032829-A1 | Process for imidazo[4,5-c]pyridin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | PAICS, HTR4, PNPO | EPHX1 2287/4885KMT2A 643/4885MAPT 1279/4885 |
| US-20050032829-A1 | Process for imidazo[4,5-c]pyridin-4-amines | PAICS, HTR4, PNPO | EPHX1 2287/4885KMT2A 643/4885MAPT 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.